Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Novel developmental therapeutics at ESMO 2026: pumitamig, IBI363 & JMT108

Valentina Boni • 26 Oct 2026
ESMO 2026
General Antibodies IBI363 JMT108 Pumitamig

Valentina Boni, MD, PhD, Universitary Hospital Quirónsalud Madrid, Madrid, Spain, discusses the emerging trends in cancer therapeutics, highlighting the potential of bispecific antibodies, antibody-drug conjugates (ADCs), and immunotherapies. Drugs of note include pumitamig, a PD-L1 and VEGF-A bispecific antibody, IBI363 (TAK-928), and JMT108, a novel anti-PD-1/IL-15 bifunctional fusion protein, in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Valentina Boni

Assessing ISM6331, an AI-designed pan-TEAD inhibitor, in advanced solid tumors
1:59
Assessing ISM6331, an AI-designed pan-TEAD inhibitor, in advanced solid tumors
Valentina Boni • 26 Oct 2026
Next-generation KRAS inhibitors at ESMO 2026: FMC-376 and INCB161734
3:41
Next-generation KRAS inhibitors at ESMO 2026: FMC-376 and INCB161734
Valentina Boni • 26 Oct 2026
Promising new ADCs
1:25
Promising new ADCs
Valentina Boni • 4 Jun 2023
Overcoming the challenges faced in identifying novel targets for ADC development
2:42
Overcoming the challenges faced in identifying novel targets for ADC development
Valentina Boni • 4 Jun 2023

Related Videos

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
What financial challenges patients and healthcare systems face in oncology?
1:11
What financial challenges patients and healthcare systems face in oncology?
Daniel Goldstein • 23 Oct 2026
How can we enhance the efficacy of TILs therapy in solid tumors?
2:27
How can we enhance the efficacy of TILs therapy in solid tumors?
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals